NDLI: Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Content Provider	PubMed Central
Author	Burghaus, Rolf Coboeken, Katrin Gaub, Thomas Kuepfer, Lars Anke, Sensse Siegmund, Hans-ulrich Weiss, Wolfgang Mueck, Wolfgang Lippert, Joerg
Editor	Uversky, Vladimir N.
Abstract	Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinical development for the treatment of thromboembolic disorders. Its mechanism of action is antithrombin independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect thrombin/Factor Xa inhibitor) and dabigatran (a direct thrombin inhibitor). A blood coagulation computer model has been developed, based on several published models and preclinical and clinical data. Unlike previous models, the current model takes into account both the intrinsic and extrinsic pathways of the coagulation cascade, and possesses some unique features, including a blood flow component and a portfolio of drug action mechanisms. This study aimed to use the model to compare the mechanism of action of rivaroxaban with that of warfarin, and to evaluate the efficacy and safety of different rivaroxaban doses with other anticoagulants included in the model. Rather than reproducing known standard clinical measurements, such as the prothrombin time and activated partial thromboplastin time clotting tests, the anticoagulant benchmarking was based on a simulation of physiologically plausible clotting scenarios. Compared with warfarin, rivaroxaban showed a favourable sensitivity for tissue factor concentration inducing clotting, and a steep concentration–effect relationship, rapidly flattening towards higher inhibitor concentrations, both suggesting a broad therapeutic window. The predicted dosing window is highly accordant with the final dose recommendation based upon extensive clinical studies.
Related Links	http://dx.doi.org/10.1371/journal.pone.0017626
Starting Page	17626
File Format	PDF
ISSN	19326203
e-ISSN	19326203
Journal	PLoS ONE
Issue Number	4
Volume Number	6
Language	English
Publisher	Public Library of Science
Publisher Date	2011-04-01
Access Restriction	Open
Rights Holder	Public Library of Science
Subject Keyword	Biochemistry, Genetics and Molecular Biology(all) Agricultural and Biological Sciences(all) Medicine(all) Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Multidisciplinary

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Evaluation of a Murine Single-Blood-Injection SAH Model

Biomaterial Constructs for Delivery of Multiple Therapeutic Genes: A Spatiotemporal Evaluation of Efficacy Using Molecular Beacons

Efficacy and Safety of Using Antifibrinolytic Agents in Spine Surgery: a Meta-Analysis

Correction: Evaluation of a Murine Single-Blood-Injection SAH Model

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays

Origin of Serpin-Mediated Regulation of Coagulation and Blood Pressure

Retrospective Evaluation of New Chinese Diagnostic Scoring System for Disseminated Intravascular Coagulation

Mathematical Modeling of Intravascular Blood Coagulation under Wall Shear Stress

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Similar Documents

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Evaluation of a Murine Single-Blood-Injection SAH Model

Biomaterial Constructs for Delivery of Multiple Therapeutic Genes: A Spatiotemporal Evaluation of Efficacy Using Molecular Beacons

Efficacy and Safety of Using Antifibrinolytic Agents in Spine Surgery: a Meta-Analysis

Correction: Evaluation of a Murine Single-Blood-Injection SAH Model

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays

Origin of Serpin-Mediated Regulation of Coagulation and Blood Pressure

Retrospective Evaluation of New Chinese Diagnostic Scoring System for Disseminated Intravascular Coagulation

Mathematical Modeling of Intravascular Blood Coagulation under Wall Shear Stress

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation